Savara Inc (SVRA)

Savara Inc. announced that its Phase 3 IMPALA-2 data for molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP) will be presented at the ERS Congress in Barcelona in September 2026, showcasing long-term efficacy, safety, and biomarker findings. While this reinforces the scientific story of molgramostim, the core investment narrative for Savara hinges on the upcoming FDA approval in November 2026, with the company facing risks like regulatory outcomes, lack of revenue, and widening losses. Investors should consider these factors and other valuation perspectives beyond the ERS data.

Savara Inc. reported a wider second-quarter loss of $40.2 million, or 16 cents per share, as it expanded its commercial operations in anticipation of a November 22 FDA decision on its rare-disease drug, MOLBREEVI. The company's general and administrative expenses increased significantly due to higher personnel costs and infrastructure building for the potential U.S. market launch. Savara ended the quarter with strong cash reserves and expects decisions on MOLBREEVI from European and U.K. regulators in late 2026 and early 2027, respectively.

Savara Inc. will present results from its Phase 3 IMPALA-2 clinical trial for molgramostim inhalation solution in autoimmune pulmonary alveolar proteinosis (aPAP) at the European Respiratory Society (ERS) Congress in September 2026. The presentations will cover long-term efficacy, safety, and improvements in lung function, exercise capacity, and quality of life for patients. The company will also host an industry mini-symposium on aPAP.

Savara Inc. (NASDAQ:SVRA) announced that data from its Phase 3 IMPALA-2 clinical trial for molgramostim will be presented at the ERS Congress in Barcelona from September 5-9, 2026. These presentations will include an oral presentation on long-term efficacy and safety, and two poster presentations on exercise capacity improvements and biomarker levels. Molgramostim is a recombinant human granulocyte-macrophage colony-stimulating factor in development for autoimmune pulmonary alveolar proteinosis, a rare lung disease with no approved pharmacologic treatments.

Savara (SVRA) is attracting attention after reporting a net loss of US$40.23 million and filing a US$108.297 million shelf registration, despite its share price showing a 76.9% one-year return. The company's stock trades at a high price-to-book ratio of 9.9x, significantly above industry averages, suggesting investors are paying a premium based on expectations for its rare respiratory disease pipeline, specifically the Phase 3 molgramostim program. However, ongoing losses and the new shelf registration could temper investor sentiment.